PDLIM7 and myeloid sarcoma: Initially designed as a potential vaccine for diseases associated with an EBV latency II profile, it has proven very efficient at preferentially expanding EBNA1 and LMP1 & 2‐specific CD8+ T cells from healthy volunteers, cancer patients and MS patients and has been used in multiple clinical studies.9, 30, 68, 69